Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2793149 | 1.00 | CHRM3 (0.44) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2935980 | 0.99 | CHRM3 (0.43) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2935981 | 0.99 | CHRM3 (0.43) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2795565 | 0.94 | CHRM3 (0.46) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2795566 | 0.94 | CHRM3 (0.46) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2934896 | 0.93 | CHRM3 (0.46) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2793191 | 0.91 | CHRM3 (0.52) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2793189 | 0.91 | CHRM3 (0.52) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2933375 | 0.90 | CHRM3 (0.52) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2794066 | 0.90 | CHRM3 (0.48) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206499-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2010-07-14 | — | — | EP | claimed |
| US-20100168132-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PRESS NEIL JOHN | 2010-07-01 | — | — | US | claimed |
| US-20090048281-A1 | (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | claimed |
| EP-1811999-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-08-01 | — | — | EP | claimed |
| WO-2006048225-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | claimed |
| US-8084463-B2 | Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| EP-2206499-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20100168132-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PRESS NEIL JOHN | 2010-07-01 | — | — | US | disclosed |
| US-7723356-B2 | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | NOVARTIS AG (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20090048281-A1 | (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1811999-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006048225-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048281-A1 | (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20100168132-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.